TELCON RF PHARMACEUTICAL. Inc. Stock

Equities

A200230

KR7200230001

Communications & Networking

End-of-day quote Korea S.E. 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
783 KRW +3.71% Intraday chart for TELCON RF PHARMACEUTICAL. Inc. +5.67% -10.31%
Sales 2022 27.83B 20.18M Sales 2023 36.31B 26.32M Capitalization 97.67B 70.81M
Net income 2022 -42.08B -30.51M Net income 2023 13.91B 10.08M EV / Sales 2022 4.7 x
Net Debt 2022 20.54B 14.89M Net Debt 2023 16.9B 12.26M EV / Sales 2023 3.16 x
P/E ratio 2022
-2.56 x
P/E ratio 2023
8.48 x
Employees 113
Yield 2022 *
-
Yield 2023
-
Free-Float 75.55%
More Fundamentals * Assessed data
Dynamic Chart
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
Abion Inc. announced that it has received KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
Abion Inc. announced that it expects to receive KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc. CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 6 billion in funding from Abion Inc. CI
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
TELCON RF PHARMACEUTICAL. Inc.(KOSDAQ:A200230) dropped from S&P Global BMI Index CI
TELCON RF PHARMACEUTICAL. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TELCON RF PHARMACEUTICAL. Inc. Auditor Raises 'Going Concern' Doubt CI
KPM TECH Co., Ltd. announced that it has received KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
KPM TECH Co., Ltd. announced that it expects to receive KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety Approval to Conduct Phase 1 Study of Lenzilumab CI
Humanigen, Inc Announces the Execution of Licensing Agreement with Telcon Rf Pharmaceutical, Inc. and KPM Tech Co., Ltd CI
More news
1 day+3.71%
1 week+5.67%
Current month-2.61%
1 month-2.61%
3 months+0.51%
6 months+12.66%
Current year-10.31%
More quotes
1 week
747.00
Extreme 747
801.00
1 month
686.00
Extreme 686
890.00
Current year
625.00
Extreme 625
1 000.00
1 year
625.00
Extreme 625
1 280.00
3 years
625.00
Extreme 625
5 450.00
5 years
625.00
Extreme 625
12 250.00
10 years
625.00
Extreme 625
19 450.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-06-07
Director of Finance/CFO 48 19-03-27
Chief Tech/Sci/R&D Officer 46 00-04-30
Members of the board TitleAgeSince
Director/Board Member 54 16-07-13
Director of Finance/CFO 48 19-03-27
Director/Board Member 46 19-03-27
More insiders
Date Price Change Volume
24-04-29 783 +3.71% 372,406
24-04-26 755 -1.31% 286,728
24-04-25 765 -0.13% 365,733
24-04-24 766 +1.46% 338,883
24-04-23 755 +1.89% 503,204

End-of-day quote Korea S.E., April 28, 2024

More quotes
TELCON RF PHARMACEUTICAL. Inc., formerly TELCON.Inc, is a Korea-based company principally engaged in the manufacture and distribution of connectors and cable assemblies. The Company’s products mainly consist of radio frequency (RF) connectors, RF cables, couplers, dividers, arrestors, terminations, adapters, and other cable assemblies, which are used for wireless communication equipment.
More about the company
  1. Stock Market
  2. Equities
  3. A200230 Stock